ALAPIS Α.Β.Ε.Ε.
9- month 2007 Consolidated Financial Results
Athens, 5 November 2007: In the first nine months of 2007, ALAPIS Group of Companies ("ALAPIS" or the "Group") turnover amounted to EUR 222.8 mil., while consolidated EBITDA stood at EUR 66.9 mil and earnings after tax and minorities reported at EUR 45.6 mil.
In more detail for the 9-month period, the Healthcare division (Human and Veterinary) turnover amounted to EUR 112.4 mil., while EBITDA stood at EUR 41.2 mil., contributing the highest profit margin of all other sectors.
For the Non-Health division (Detergents & Cosmetics and Organic products) 9-month turnover totaled EUR 110.4 mil., while EBITDA reached EUR 25.7 mil.
The Group also prepared pro forma financial results, which consist of the results of the absorbed group of companies Elpharma, Lamda Detergent, Ebik for the period 1/1 - 30/9/2007 as if they had been merged on 31/12/2006. Specifically pro forma consolidated turnover for the first nine months of 2007 stood at EUR 253.1 mil., pro forma consolidated EBITDA reached EUR 73.3 mil. and pro forma consolidated earnings after tax and minorities stood at EUR 49.9 mil.
For the third quarter, the Group's turnover reached EUR 89.6 mil. (+7% q-o-q), EBITDA reached EUR 27.7 mil. (+4% q-o-q) and consolidated earnings after tax and minorities stood at EUR 21.4 mil. (+30% q-o-q).
For the avoidance of doubt, our 9-month and our profoma 2007 financial results include the results of the companies acquired by the Group during the third quarter from the date of their acquisition (excluding the acquisition of Biochem which is currently being finalised).
Based on the Group's financial performance to date, its operating growth rate and its recent successful acquisitions, the Group reiterates its financial guidance for FY 2007 and FY 2008:
FY 2007(e): Turnover: EUR 360 - 380 mil., EBITDA EUR 90 - 105 mil. and earnings after tax and minority rights: EUR 55 - 60 mil.
FY 2008(e): Turnover: EUR 700 - 725 mil., EBITDA EUR 190 - 210 mil. and earnings after tax and minority rights EUR 120 - 130 mil.
The above projections are only management estimates and are only an indication of the group's future operational performance. The management of ALAPIS is monitoring closely the trends and developments in the markets it operates in, as well as the general macroeconomic environment of the countries in which it is active and any other circumstances that may materially impact its financial objectives as they are presented herein and will inform the investment community in a timely manner, should any such case arise, as it has systematically been doing so far.
In more detail for the 9-month period, the Healthcare division (Human and Veterinary) turnover amounted to EUR 112.4 mil., while EBITDA stood at EUR 41.2 mil., contributing the highest profit margin of all other sectors.
For the Non-Health division (Detergents & Cosmetics and Organic products) 9-month turnover totaled EUR 110.4 mil., while EBITDA reached EUR 25.7 mil.
The Group also prepared pro forma financial results, which consist of the results of the absorbed group of companies Elpharma, Lamda Detergent, Ebik for the period 1/1 - 30/9/2007 as if they had been merged on 31/12/2006. Specifically pro forma consolidated turnover for the first nine months of 2007 stood at EUR 253.1 mil., pro forma consolidated EBITDA reached EUR 73.3 mil. and pro forma consolidated earnings after tax and minorities stood at EUR 49.9 mil.
For the third quarter, the Group's turnover reached EUR 89.6 mil. (+7% q-o-q), EBITDA reached EUR 27.7 mil. (+4% q-o-q) and consolidated earnings after tax and minorities stood at EUR 21.4 mil. (+30% q-o-q).
For the avoidance of doubt, our 9-month and our profoma 2007 financial results include the results of the companies acquired by the Group during the third quarter from the date of their acquisition (excluding the acquisition of Biochem which is currently being finalised).
Based on the Group's financial performance to date, its operating growth rate and its recent successful acquisitions, the Group reiterates its financial guidance for FY 2007 and FY 2008:
FY 2007(e): Turnover: EUR 360 - 380 mil., EBITDA EUR 90 - 105 mil. and earnings after tax and minority rights: EUR 55 - 60 mil.
FY 2008(e): Turnover: EUR 700 - 725 mil., EBITDA EUR 190 - 210 mil. and earnings after tax and minority rights EUR 120 - 130 mil.
The above projections are only management estimates and are only an indication of the group's future operational performance. The management of ALAPIS is monitoring closely the trends and developments in the markets it operates in, as well as the general macroeconomic environment of the countries in which it is active and any other circumstances that may materially impact its financial objectives as they are presented herein and will inform the investment community in a timely manner, should any such case arise, as it has systematically been doing so far.